
GI CANCERS
Latest News
Video Series

Latest Videos
Shorts










Podcasts
CME Content
More News

Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.

Zev A. Wainberg, MD, MSc, reviews RASolute 302 findings on daraxonrasib's OS benefit across RAS genotypes in metastatic pancreatic cancer.

ESMO 2026 unveils GI cancer advances: targeted and immunotherapy regimens boost survival in pancreatic, colorectal, gastric, and HER2+ gastroesophageal disease.

ESMO 2026: Divarasib, Savolitinib, Ivonescimab Show OS Gains in Phase 3 Trials
ESMO 2026 Presidential Symposium II recap: Survival benefits were reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.

The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.

The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.

Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy for rectal cancer and when watch-and-wait is feasible.

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.

The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.

The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.

This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.

The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.

RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.

The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.









































